Efficacy and Safety of a Fixed Various-Dose Combination of Valsartan and Hydrochlorothiazide: the Results of Ukrainian Cooperative Study ВАГНЕР (Valsacor in High-Risk Hypertension)


  • L.H. Voronkov
  • Ye.P. Svishchenko
  • A.E. Bahrii
  • L.S. Vaida
  • et al.




hypertension, microalbuminuria, combined drug, valsartan, hydrochlorothiazide


The article presents the data of Ukrainian coope­rative study ВАГНЕР on the effectiveness of combined tablet dosage form containing valsartan and hydrochlorothiazide. It is proved that the use of combined forms of valsartan and hydrochlorothiazide (the drugs Valsacor Н 80/Valsacor Н 160/Valsacor НD 160) provides the achievement of target blood pressure levels in 72 % of patients with high-risk hypertension. 16-week controlled administration of these combined forms is associated with a considerable reduction in the key indicators of the blood pressure, a significant reduction of microalbuminuria and a significant regression of left ventricular hypertrophy due to the high tolerance of the treatment.


Mancia G., Fagard R., Narkiewicz K. et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cаrdiology (ESC) // J. Hypertens. — 2013. — Vol. 31, № 7. — Р. 1281-1357.

Polter N. Multiple combination therapy in hypertension. — Nova Prof. Media Ltd., 2014. — 117 p.

Карпов Ю.А. Валсартан: центральное место в лечении кардиологического больного // Атмосферa. Новости кардиологии. — 2011. — 2. — http://atm-press.ru

Nixon R.M., Muller E., Lowy A. еt al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach // Int. J. Clin. Pract. — 2009. — Vol. 5. — Р. 766-775.

Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial // Lancet. — 2004. — Vol. 363. — Р. 2022-2031.

Kingbeil A.U., Schneider M., Martus P. et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension // Am. J. Med. — 2003. — Vol. 115 (1). — Р. 41-46.

Ibsen H., Olsen M., Wachtell K. еt al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study // Hypertension. — 2005. — Vol. 45. — Р. 198-202.

Viberti G. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure — independent effect. Wheeldon and for the microalbuminuria reduction with VALsartan (MARVAL) study investigators // Circulation. — 2002. — Vol. 106. — Р. 672-8.

McMurray J., Solomon S., Pieper K. еt al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction. An analysis of the valsartan in acute myocardial infarction trial (VALIANT) // J. Am. Coll. Cardiol. — 2006. — Vol. 47. — Р. 726-33.

Peters S., Gotting B., Trummel M. et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial // J. Invasive Cardiol. — 2001. — Vol. 13. — № 2. — Р. 93-97.

Peters S., Trummel M., Meyners W. et al. Valsartan versus ACE inhibition after metal stent implantation — results of the VALVACE trial // Int. J. Cardiol. — 2005. — Vol. 98. — № 2. — Р. 331-335.

Mochizuki S., Dahluf B., Shimizu M. et al. Valsartan in Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study // Lancet. — 2007. — Vol. 369. — Р. 1431-1439.

Sawada T., Yamada H., Dahlof B. et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risk: KYOTO HEART Study // Eur. Heart. J. — 2009. — Vol. 30 (20). — Р. 2461-2469.

World Preview 2018, аналітичний звіт (Evaluate Pharma).


Chapmen R.H., Benner J.S., Petrilla A.A. et al. Predictors of adherence with antihypertensive and lipid-lowering therapy // Arch. Intern. Med. — 2005. — Vol. 165 (10). — Р. 1147-1152.

Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis // Amer. J. Med. — 2007. — Vol. 120 (8). — Р. 713-719.

Радченко А.Д., Торбас Е.А., Доброход А.С. Оценка эффективности фиксированной комбинации валсартана и гидрохлортиазида в лечении больных с неосложненной умеренной и тяжелой артериальной гипертензией: результаты 6-месячного наблюдения // Укр. кардіолог. журнал. — 2013. — № 1. — С. 69-81.

Свищенко Е.П., Матова Е.А., Мищенко Л.А. Диастолическая дисфункция ЛЖ у больных гипертонической болезнью: возможности коррекции с помощью валсартана // Артериальная гипертензия. — 2012. — № 2. — С. 39-46.

European Society of Hypertension practice guidelines for home blood pressure monitoring // J. Hum Hypertens. — 2010. — Vol. 24. — Р. 779-785.

Weir M.R., Levy D., Crikelair N. et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy // Am. J. Hypertens. — 2007 Jul. — Vol. 20 (7). — Р. 807-15.

Іванов В.П. Лікування пацієнтів із артеріальною гіпертензією і високим серцево-судинним ризиком в умовах поліклінічної практики України // Здоров’я України. — 2011. — № 13–14. — С. 1-4.

Bombelli M., Facchetti R., Carugo S. et al. Left ventri­cular hypertrophy ingreases cardiovascular risk independently of in- and out-of office blood pressure values // J. Hypertension. — 2009. — Vol. 27. — Р. 2458-2464.

Go A., Chertow G., Fan D. et al. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization // N. Engl. J. Med. — 2004. — Vol. 351. — Р. 1296-1305.

Mourad J.J., Waeber B., Zannad F. et al. Investiga­tirs of the STRATHE trial. Comparison of different therapeutic in hypertension: a low-dose combination of perendopril/inda­pamide versus a sequential monotherapy or a stepped-care approach // J. Hypertens. — 2004. — № 22. — Р. 2379-2386.



Clinical Researches